Debiopharm is a privately-held Swiss biopharmaceutical company focused on developing and out-licensing innovative compounds, primarily in oncology and infectious diseases. The company's unique business model involves in-licensing promising drug candidates, conducting clinical development, and then partnering with larger pharmaceutical companies for global commercialization. Additionally, Debiopharm is active in drug manufacturing and strategic investments in digital health and smart data start-ups.